Targeting disease where it matters
The AND-Platform™ enables a new way of designing medicines by reimagining the definition of a target. By decoupling the burden of specificity from the needed biological effect, we are able to unlock a new targeting axis for precisely localizing medicines. The core of our platform includes a proprietary Address Map. Powered by a computational engine, the AND-Platform continually learns the rules for identifying optimal localizer targets and refines its ability to design across the complex space of locators and actuators. The Platform optimizes in multiple dimensions efficiently to produce increasingly sophisticated AND-Body medicines.
The Address Map is based on a comprehensive multi-omics characterization of human biology, spanning healthy and diseased states. The platform is trained to explore an unprecedented targeting landscape to select ideal localizing targets optimally chosen for druggability and fitness in the disease. This is the foundation of every AND-Body.
To unlock novel medicines, we've developed both a high-throughput binder generation capability built on a state-of-the-art microfluidics platform, and an AI-guided binder prediction strategy. Combined with our integrated modeling and screening capabilities as well as our antibody discovery and development capabilities from our wholly-owned subsidiary AbCheck, we can rapidly generate and test binders to new locator and actuator targets, while continually learning the rules that enable our molecules to navigate to their intended targets.
We engineer AND-Body medicines across the physical constraints of molecules and the biological characteristics of the targets. Once ideal components are identified, we can build AND-Body therapeutics across a host of formats using a range of molecules, including proteins, small molecules, LNPs, or nucleic acids that are designed to act as intended, conditionally at the site of disease.